cysteamine has been researched along with gemfibrozil in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bodas, M; Gulbins, E; Pehote, G; Silverberg, D; Vij, N | 1 |
1 review(s) available for cysteamine and gemfibrozil
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for cysteamine and gemfibrozil
Article | Year |
---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Autophagy augmentation alleviates cigarette smoke-induced CFTR-dysfunction, ceramide-accumulation and COPD-emphysema pathogenesis.
Topics: Acid Ceramidase; Animals; Antioxidants; Autophagy; Bronchi; Case-Control Studies; Cell Line; Ceramides; Complex Mixtures; Cysteamine; Cystic Fibrosis Transmembrane Conductance Regulator; Emphysema; Epithelial Cells; Gemfibrozil; Gene Expression; Humans; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Nicotiana; Pulmonary Disease, Chronic Obstructive; Smoking | 2019 |